North America Drug Delivery Devices Market – Industry Trends and Forecast to 2031

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

North America Drug Delivery Devices Market – Industry Trends and Forecast to 2031

  • Medical Devices
  • Upcoming Report
  • Aug 2024
  • North America
  • 175 Pages
  • No of Tables: 170
  • No of Figures: 29

North America Drug Delivery Devices Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2024 –2031
Diagram Market Size (Base Year)
USD 788.49 Billion
Diagram Market Size (Forecast Year)
USD 1,351.11 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Panacea Biotec Ltd
  • AptarGroup
  • Koninklijke Philips N.V.
  • Nemera
  • Biocorp Production

North America Drug Delivery Devices Market, By Product Type (Oral Drug DeliveryInjectable Drug Delivery, Topical Drug Delivery, Ophthalmic Drug Delivery, Nasal Drug DeliveryPulmonary Drug Delivery, Transmucosal Drug Delivery, and Implantable Drug Delivery), End User (Hospitals, Home Healthcare, Clinics, Community Healthcare and Others), Distribution Channel (Direct Tenders, Hospital Pharmacies, Pharmacy Stores, and Online Pharmacy) - Industry Trends and Forecast to 2031.

North America Drug Delivery Devices Market

 

North America Drug Delivery Devices Market Analysis and Size

The north america drug delivery devices market is experiencing significant growth, driven by the rising prevalence of chronic disease and non-chronic disease, growth in the development of biologics drugs devices, and increasing awareness about diagnosis and treatment. The market is characterized by the presence of a large number of players offering a wide range of diagnostic devices tailored to meet the diverse needs of healthcare providers in the region.

Data Bridge Market Research analyzes that the North America drug delivery devices market is growing with a CAGR of 7.3% in the forecast period of 2024 to 2031 and is expected to reach USD 1,351.11 billion by 2031 from USD 788.49 billion in 2023.

Report Metric

Details

Forecast Period

2024 to 2031

Base Year

2023

Historic Year

2022 (Customizable 2016-2021)

Quantitative Units

Revenue in USD Billion

Segments Covered

Product Type (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ophthalmic Drug Delivery, Nasal Drug Delivery, Pulmonary Drug Delivery, Transmucosal Drug Delivery, and Implantable Drug Delivery), End User (Hospitals, Home Healthcare, Clinics, Community Healthcare and Others), Distribution Channel (Direct Tenders, Hospital Pharmacies, Pharmacy Stores, and Online Pharmacy)

Countries Covered

U.S., Canada, and Mexico

Market Players Covered

BD, F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, Johnson & Johnson Services, Inc., 3M, Gerresheimer AG, Medmix, OraSure Technologies Inc., Enable Injection, Insulet Corporation, Bayer AG, Pfizer Inc., GSK plc., Merck & Co., Inc., Amgen Inc., AbbVie Inc., Elcam Medical, SMC Ltd., ViVO Smart Medical Devices Ltd., West and Pharmaceutical Services, Inc. among others

Market Definition

Drug delivery devices are medical devices designed to deliver medications to the body in a controlled and targeted manner, enhancing their efficacy, safety, and patient compliance. These devices can be external, such as inhalers, injectors, and pumps, or internal such as implantable devices, and are used to administer a wide range of medications, including small molecules, biologics, and vaccines. They can modify the release rate, bioavailability, and absorption of drugs, as well as provide real-time monitoring and feedback to patients and healthcare providers. Drug delivery devices play a crucial role in optimizing treatment outcomes and improving patient quality of life for various diseases and conditions, including chronic conditions, infectious diseases, and cancer.

North America Drug Delivery Devices Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:

Drivers

  • Rising Prevalence of Chronic Disease and Non-Chronic Disease

The prevalence of diseases and conditions such as Cardiovascular Diseases (CVDs), asthma, cancer, neurological disorders, stroke, diabetes, and respiratory diseases has increased significantly over some time. Mentioned below are some of the important statistics related to some of the chronic diseases. The rising prevalence of chronic and non-chronic diseases significantly influences the growth of the drug delivery devices market. Chronic diseases such as diabetes, cardiovascular diseases, and respiratory disorders are becoming more widespread, necessitating long-term treatment plans that require efficient and reliable drug delivery device methods.

  • Growth in the Development of Biologics Drugs Devices

Biologics is considered one of the fastest-growing segments in the pharmaceutical market. Development and manufacturing of biologics for both branded and generic drugs is becoming increasingly competitive with the presence of players. Biologics are generally administered through injections in the arms, legs or abdomen. For instance, Cimzia, Cosentyx, Enbrel, and Humira among others.

Opportunity

  • Rising Acceptance of Self-Administering Drug Devices

Self-administration of drugs by the patients is expected to provide significant growth opportunities for drug delivery players focusing on the development of innovative and new devices. Major factors contributing to this are growing elderly population, as aged population forms large consumer base for homecare drug delivery devices. Pharmaceutical companies are focusing on the development of patient-friendly therapies and self-administered drug-device combination products. With the increasing acceptance of self-administration, the need for application-specific injection, inhalation, topical, and transdermal drug products is also increasing.

Restraint/Challenge

  • Side Effects of Drug Delivery Systems

Adverse reactions to drug delivery systems can lead to a decrease in patient compliance, which can result in decreased demand for the device. This can negatively impact the sales and revenue of the device manufacturer. Side effects can raise concerns about patient safety, leading to increased scrutiny and regulation from regulatory agencies. This can lead to delays in product launches, additional testing requirements, and increased costs for device manufacturers. Moreover, side effects can lead to device rejection by patients, resulting in a decrease in demand for the device. This can be particularly problematic for devices that require long-term use, such as implantable devices.

Recent Developments

  • In August 2023, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. submitted the supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking sanction of DARZALEX in combination with Kyprolis and dexamethasone for relapsed/refractory multiple myeloma. If approved this will increase the product portfolio and also revenue generation of the company
  • In January 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. announced that EC has given the grant to market Erleada which is used to treat metastatic hormone-sensitive prostate cancer (mHSPC) in combination with Androgen Deprivation Therapy (ADT). This will increase their market presence which will further increase the revenue generation
  • In December 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. announced the EC approval of SPRAVATO nasal spray, which will enhance their product portfolio which will further increase the revenue

North America Drug Delivery Devices Market Scope

The North America drug delivery devices market is segmented into three notable segments based on product type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Product Type

  • Oral Drug Delivery
  • Injectable Drug Delivery
  • Topical Drug Delivery
  • Ophthalmic Drug Delivery
  • Nasal Drug Delivery
  • Pulmonary Drug Delivery
  • Transmucosal Drug Delivery
  • Implantable Drug Delivery

On the basis of product type, the North America drug delivery devices market is segmented into injectable drug delivery formulations, injectable drug delivery, topical drug delivery, ophthalmic drug delivery, nasal drug delivery, pulmonary drug delivery, transmucosal drug delivery, and implantable drug delivery.

End User

  • Hospitals
  • Home Healthcare
  • Clinics
  • Community Healthcare
  • Others

On the basis of end user, the North America drug delivery devices market is segmented into hospitals, home healthcare, clinics, community healthcare and others.

Distribution Channel

  • Direct Tenders
  • Hospital Pharmacies
  • Pharmacy Stores
  • Online Pharmacy

On the basis of distribution channel, the North America drug delivery devices market is segmented into direct tenders, hospital pharmacies, pharmacy stores, and online pharmacy.

North America Drug Delivery Devices Market Regional Analysis/Insights

North America Drug Delivery Devices Market is analyzed, and market size insights and trends are provided by based on product type, end user, and distribution channel as referenced above.

The countries covered in this market report are U.S., Canada, and Mexico.

North America is expected to dominate the market due to factors such as its advanced healthcare infrastructure, high R&D investment, and strong demand for innovative medical technologies.

The U.S. is expected to dominate in the North America market due to its advanced healthcare infrastructure, significant investment in research and development, and a robust regulatory framework that supports innovation.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and North America Drug Delivery Devices Market Share Analysis

The North America drug delivery devices market is segmented into three notable segments based on product type, end user, and distribution channel..

The North America drug delivery devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the North America drug delivery devices market.

Some of the major players operating in the the North America drug delivery devices market are BD, F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, Johnson & Johnson Services, Inc., 3M, Gerresheimer AG, Medmix, OraSure Technologies Inc., Enable Injection, Insulet Corporation, Bayer AG, Pfizer Inc., GSK plc., Merck & Co., Inc., Amgen Inc., AbbVie Inc., Elcam Medical, SMC Ltd., ViVO Smart Medical Devices Ltd., West and Pharmaceutical Services, Inc. among others.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USER COVERAGE GRID

2.8 PRODUCT TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTERS FIVE FORCES

4.2 PESTEL ANALYSIS

5 REGULATORY FRAMEWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE

6.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS DRUGS DEVICES

6.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT

6.1.4 INCREASED FOCUS ON PERSONALIZED MEDICINE AND DEVICES

6.2 RESTRAINTS

6.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS

6.2.2 HIGH COSTS OF INJECTABLE DRUGS

6.2.3 STRINGENT REGULATORY SCENARIO

6.3 OPPORTUNITIES

6.3.1 RISING ACCEPTANCE OF SELF-ADMINISTERING DRUG DEVICES

6.3.2 RISING DEMAND FOR BIOSIMILAR AND GENERIC DRUGS

6.3.3 THERAPEUTIC ADVANCEMENTS IN THE FIELD OF DRUG DELIVERY

6.4 CHALLENGES

6.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS

6.4.2 INCREASE IN THE NUMBER OF ALTERNATIVES OF DRUG DELIVERY

7 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 ORAL DRUG DELIVERY

7.2.1 SOLID ORAL DRUGS

7.2.1.1 TABLETS

7.2.1.2 CAPSULES

7.2.1.3 PILLS

7.2.1.4 POWDERS

7.2.2 LIQUID ORAL DRUGS

7.2.2.1 SYRUPS

7.2.2.2 SOLUTIONS

7.2.3 SEMI SOLID ORAL DRUGS

7.2.3.1 GELS

7.2.3.2 EMULSIONS

7.2.3.3 ELIXIRS

7.3 INJECTABLE DRUG DELIVERY

7.3.1 INJECTABLE DRUG DELIVERY FORMULATIONS

7.3.1.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS

7.3.1.2 NOVEL DRUG DELIVERY FORMULATIONS

7.3.1.3 LONG ACTING INJECTION FORMULATIONS

7.3.2 INJECTABLE DRUG DELIVERY DEVICES

7.3.2.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES

7.3.2.1.1 BY MATERIAL

7.3.2.1.1.1 GLASS

7.3.2.1.1.2 PLASTIC

7.3.2.1.2 BY PRODUCT TYPE

7.3.2.1.2.1 FILLABLE

7.3.2.1.2.2 PRE-FILLED

7.3.2.1.3 BY USABILITY

7.3.2.1.3.1 REUSABLE SYRINGES

7.3.2.1.3.2 DISPOSABLE SYRINGES

7.3.2.2 SELF INJECTION DRUG DELIVERY DEVICES

7.3.2.2.1 NEEDLE FREE INJECTORS

7.3.2.2.2 WEARABLE INJECTORS

7.3.2.2.3 PEN INJECTOR

7.3.2.2.4 AUTO INJECTORS

7.3.2.2.5 OTHERS

7.4 TOPICAL DRUG DELIVERY

7.4.1 TRANSDERMAL DRUG DELIVERY FORMULATIONS

7.4.1.1 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS

7.4.1.1.1 OINTMENTS

7.4.1.1.2 CREAMS

7.4.1.1.3 LOTIONS

7.4.1.1.4 GELS

7.4.1.1.5 PASTES

7.4.1.2 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS

7.4.1.2.1 SUSPENSIONS

7.4.1.2.2 SOLUTIONS

7.4.1.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS

7.4.1.3.1 POWDER

7.4.1.3.2 SUPPOSITORS

7.5 OPHTHALMIC DRUG DELIVERY

7.5.1 OCCULAR DRUG DELIVERY FORMULATIONS

7.5.1.1 LIQUID OCCULAR DRUG DELIVERY FORMULATIONS

7.5.1.1.1 SOLUTIONS

7.5.1.1.2 SUSPENSIONS

7.5.1.2 SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS

7.5.1.2.1 GELS

7.5.1.2.2 OINTMENTS

7.5.2 OCCULAR DRUG DELIVERY DEVICES

7.6 NASAL DRUG DELIVERY

7.6.1 NASAL DROPS

7.6.2 NASAL SPRAYS

7.6.3 NASAL POWDERS

7.6.4 NASAL GELS

7.7 PULMONARY DRUG DELIVERY

7.7.1 METERED DOSE INHALERS (MDI)

7.7.2 DRY POWDER INHALERS (DPI)

7.7.3 NEBULIZERS

7.7.3.1 JET NEBULIZERS

7.7.3.2 ULTRASONIC NEBULIZERS

7.7.3.3 SOFT MIST NEBULIZERS

7.8 TRANSMUCOSAL DRUG DELIVERY

7.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY

7.8.1.1 BUCCAL DRUG DELIVERY

7.8.1.2 SUBLINGUAL DRUG DELIVERY

7.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY

7.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY

7.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY

7.9 IMPLANTABLE DRUG DELIVERY

7.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES

7.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES

8 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS

8.3 HOME HEALTHCARE

8.4 CLINICS

8.5 COMMUNITY HEALTHCARE

8.6 OTHERS

9 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 DIRECT TENDERS

9.3 HOSPITAL PHARMACIES

9.4 PHARMACY STORES

9.5 ONLINE PHARMACY

10 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY REGION

10.1 NORTH AMERICA

10.1.1 U.S.

10.1.2 CANADA

10.1.3 MEXICO

11 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY LANDSCAPE

11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

12 SWOT ANALYSIS

13 COMPANY PROFILE

13.1 JOHNSON & JOHNSON SERVICES, INC.

13.1.1 COMPANY SNAPSHOT

13.1.2 REVENUE ANALYSIS

13.1.3 COMPANY SHARE ANALYSIS

13.1.4 PRODUCT PORTFOLIO

13.1.5 RECENT DEVELOPMENTS

13.2 NOVARTIS AG

13.2.1 COMPANY SNAPSHOT

13.2.2 REVENUE ANALYSIS

13.2.3 COMPANY SHARE ANALYSIS

13.2.4 PRODUCT PORTFOLIO

13.2.5 RECENT DEVELOPMENTS

13.3 F. HOFFMANN-LA ROCHE LTD

13.3.1 COMPANY SNAPSHOT

13.3.2 REVENUE ANALYSIS

13.3.3 COMPANY SHARE ANALYSIS

13.3.4 PRODUCT PORTFOLIO

13.3.5 RECENT DEVELOPMENT

13.4 BAYER AG

13.4.1 COMPANY SNAPSHOT

13.4.2 REVENUE ANALYSIS

13.4.3 COMPANY SHARE ANALYSIS

13.4.4 PRODUCT PORTFOLIO

13.5 PFIZER INC.

13.5.1 COMPANY SNAPSHOT

13.5.2 REVENUE ANALYSIS

13.5.3 COMPANY SHARE ANALYSIS

13.5.4 PRODUCT PORTFOLIO

13.5.5 RECENT DEVELOPMENT

13.6 3M

13.6.1 COMPANY SNAPSHOT

13.6.2 REVENUE ANALYSIS

13.6.3 PRODUCT PORTFOLIO

13.6.4 RECENT DEVELOPMENTS

13.7 ABBVIE INC.

13.7.1 COMPANY SNAPSHOT

13.7.2 REVENUE ANALYSIS

13.7.3 PRODUCT PORTFOLIO

13.7.4 RECENT DEVELOPMENTS

13.8 AMGEN INC.

13.8.1 COMPANY SNAPSHOT

13.8.2 REVENUE ANALYSIS

13.8.3 PRODUCT PORTFOLIO

13.8.4 RECENT DEVELOPMENTS

13.9 BD

13.9.1 COMPANY SNAPSHOT

13.9.2 REVENUE ANALYSIS

13.9.3 PRODUCT PORTFOLIO

13.9.4 RECENT DEVELOPMENT

13.1 ELCAM MEDICAL

13.10.1 COMPANY SNAPSHOT

13.10.2 PRODUCT PORTFOLIO

13.10.3 RECENT DEVELOPMENT

13.11 ENABLE INJECTIONS

13.11.1 COMPANY SNAPSHOT

13.11.2 PRODUCT PORTFOLIO

13.11.3 RECENT DEVELOPMENTS

13.12 GERRESHEIMER AG

13.12.1 COMPANY SNAPSHOT

13.12.2 REVENUE ANALYSIS

13.12.3 PRODUCT PORTFOLIO

13.12.4 RECENT DEVELOPMENTS

13.13 GSK PLC.

13.13.1 COMPANY SNAPSHOT

13.13.2 REVENUE ANALYSIS

13.13.3 PRODUCT PORTFOLIO

13.13.4 RECENT DEVELOPMENTS

13.14 INSULET CORPORATION

13.14.1 COMPANY SNAPSHOT

13.14.2 REVENUE ANALYSIS

13.14.3 PRODUCT PORTFOLIO

13.14.4 RECENT DEVELOPMENTS

13.15 MEDMIX

13.15.1 COMPANY SNAPSHOT

13.15.2 REVENUE ANALYSIS

13.15.3 PRODUCT PORTFOLIO

13.15.4 RECENT DEVELOPMENTS

13.16 MERCK & CO., INC.

13.16.1 COMPANY SNAPSHOT

13.16.2 REVENUE ANALYSIS

13.16.3 PRODUCT PORTFOLIO

13.16.4 RECENT DEVELOPMENT

13.17 ORASURE TECHNOLOGIES INC.

13.17.1 COMPANY SNAPSHOT

13.17.2 REVENUE ANALYSIS

13.17.3 PRODUCT PORTFOLIO

13.17.4 RECENT DEVELOPMENT

13.18 SANOFI

13.18.1 COMPANY SNAPSHOT

13.18.2 REVENUE ANALYSIS

13.18.3 PRODUCT PORTFOLIO

13.18.4 RECENT DEVELOPMENTS

13.19 SMC LTD.

13.19.1 COMPANY SNAPSHOT

13.19.2 REVENUE ANALYSIS

13.19.3 PRODUCT PORTFOLIO

13.19.4 RECENT DEVELOPMENTS

13.2 VIVO SMART MEDICAL DEVICES LTD.

13.20.1 COMPANY SNAPSHOT

13.20.2 PRODUCT PORTFOLIO

13.20.3 RECENT DEVELOPMENT

13.21 WEST PHARMACEUTICAL SERVICES, INC.

13.21.1 COMPANY SNAPSHOT

13.21.2 REVENUE ANALYSIS

13.21.3 PRODUCT PORTFOLIO

13.21.4 RECENT DEVELOPMENT

14 QUESTIONNAIRE

15 RELATED REPORTS

List of Table

TABLE 1 LIST OF FDA APPROVED BIOLOGICS, IN 2022

TABLE 2 10 MOST EXPENSIVE DRUGS IN THE U.S. (IN USD MILLION)

TABLE 3 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 4 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 5 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 6 NORTH AMERICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 7 NORTH AMERICA LIQUID ORAL DRUG IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 8 NORTH AMERICA SEMI SOLID ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 9 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 10 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 11 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 12 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 13 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)

TABLE 14 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE 2022-2031 (USD MILLION)

TABLE 15 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 16 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 17 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 18 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 19 NORTH AMERICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 20 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 21 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 22 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 23 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 24 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 25 NORTH AMERICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 26 NORTH AMERICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 27 NORTH AMERICA SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 28 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 29 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 30 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 31 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 32 NORTH AMERICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 33 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 34 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 35 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 36 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 37 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 38 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 39 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 40 NORTH AMERICA HOSPITALS IN DRUG DELIVERY MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 41 NORTH AMERICA HOME HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 42 NORTH AMERICA CLINICS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 43 NORTH AMERICA COMMUNITY HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 44 NORTH AMERICA OTHERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 45 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 46 NORTH AMERICA DIRECT TENDERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 47 NORTH AMERICA HOSPITAL PHARMACIES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 48 NORTH AMERICA PHARMACY STORES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 49 NORTH AMERICA ONLINE PHARMACY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 50 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 51 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 52 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 53 NORTH AMERICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 54 NORTH AMERICA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 55 NORTH AMERICA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 56 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 57 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 58 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 59 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)

TABLE 60 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 61 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 62 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 63 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 64 NORTH AMERICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 65 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 66 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 67 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 68 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 69 NORTH AMERICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 70 NORTH AMERICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 71 NORTH AMERICA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 72 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 73 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 74 NORTH AMERICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 75 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 76 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 77 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 78 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 79 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 80 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 81 U.S. DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 82 U.S. ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 83 U.S. SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 84 U.S. LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 85 U.S. SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 86 U.S. INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 87 U.S. INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 88 U.S. INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 89 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)

TABLE 90 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 91 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 92 U.S. SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 93 U.S. TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 94 U.S. TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 95 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 96 U.S. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 97 U.S. SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 98 U.S. OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 99 U.S. OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 100 U.S. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 101 U.S. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 102 U.S. NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 103 U.S. PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 104 U.S. NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 105 U.S. TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 106 U.S. ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 107 U.S. OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 108 U.S. IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 109 U.S. DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 110 U.S. DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 111 CANADA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 112 CANADA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 113 CANADA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 114 CANADA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 115 CANADA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 116 CANADA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 117 CANADA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 118 CANADA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 119 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)

TABLE 120 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 121 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 122 CANADA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 123 CANADA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 124 CANADA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 125 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 126 CANADA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 127 CANADA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 128 CANADA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 129 CANADA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 130 CANADA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 131 CANADA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 132 CANADA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 133 CANADA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 134 CANADA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 135 CANADA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 136 CANADA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 137 CANADA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 138 CANADA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 139 CANADA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 140 CANADA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 141 MEXICO DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 142 MEXICO ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 143 MEXICO SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 144 MEXICO LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 145 MEXICO SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 146 MEXICO INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 147 MEXICO INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 148 MEXICO INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 149 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)

TABLE 150 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 151 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 152 MEXICO SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 153 MEXICO TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 154 MEXICO TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 155 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 156 MEXICO LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 157 MEXICO SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 158 MEXICO OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 159 MEXICO OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 160 MEXICO LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 161 MEXICO SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 162 MEXICO NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 163 MEXICO PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 164 MEXICO NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 165 MEXICO TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 166 MEXICO ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 167 MEXICO OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 168 MEXICO IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 169 MEXICO DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 170 MEXICO DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: MARKET END USER COVERAGE GRID

FIGURE 8 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION

FIGURE 11 EXECUTIVE SUMMARY

FIGURE 12 EIGHT SEGMENTS COMPRISE THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

FIGURE 13 STRATEGIC DECISIONS

FIGURE 14 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE ARE DRIVING THE GROWTH OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET FROM 2024 TO 2031

FIGURE 15 THE ORAL DRUG DELIVERY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET IN 2024 AND 2031

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA DRUG DELIVERY DEVICES MARKET

FIGURE 17 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023

FIGURE 18 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023-2031 (USD MILLION)

FIGURE 19 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, CAGR (2024-2031)

FIGURE 20 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 21 NORTH AMERICA DRUG DELIVERY MARKET: BY END USER, 2023

FIGURE 22 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY END USER, 2024-2031 (USD MILLION)

FIGURE 23 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: END USER, CAGR (2024-2031)

FIGURE 24 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: END USER, LIFELINE CURVE

FIGURE 25 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 26 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)

FIGURE 27 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 28 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 29 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE 2023 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on , By Product Type (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ophthalmic Drug Delivery, Nasal Drug Delivery, Pulmonary Drug Delivery, Transmucosal Drug Delivery, and Implantable Drug Delivery), End User (Hospitals, Home Healthcare, Clinics, Community Healthcare and Others), Distribution Channel (Direct Tenders, Hospital Pharmacies, Pharmacy Stores, and Online Pharmacy) - Industry Trends and Forecast to 2031. .
The North America Drug Delivery Devices Market size was valued at USD 788.49 USD Billion in 2023.
The North America Drug Delivery Devices Market is projected to grow at a CAGR of 7.3% during the forecast period of 2024 to 2031.
The major players operating in the market include Panacea Biotec Ltd, AptarGroup , Koninklijke Philips N.V., Nemera, Biocorp Production, Valeritas Holdings , Ethicon, Eli Lilly and Company, Accord Healthcare , BD, Bayer AG, Johnson & Johnson Services , Novartis AG, Pfizer , F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Merck & Co., Sanofi, and 3M .
The market report covers data from the U.S., Canada, and Mexico.